Levels of Circulating Cell-Free Nuclear and Mitochondrial DNA in Benign and Malignant Ovarian Tumors
The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To analyze the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in patients with benign and malignant ovarian tumors using a gold-standard assay and to investigate whether quantitative alterations of the circulating cell-free species have values in the management of the patients. METHODS: One hundred four patients were recruited for this study. We developed a quantitative, multiplex polymerase chain reaction to measure the levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in serum and plasma of patients with epithelial ovarian cancer, benign epithelial ovarian tumors, or endometriosis. The levels of the circulating cell-free DNA were compared with those of a healthy, age-matched control group. RESULTS: The patients with epithelial ovarian cancer had significantly higher amounts of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in plasma compared with the healthy control group (mean of nuclear DNA 10,723/2,591 and mean of mitochondrial DNA 4,918,978/2,294,264, P=.009 and 0.022, respectively) and with the other group with benign ovarian diseases (mean of nuclear DNA 10,723/2,965 and mean of mitochondrial DNA 4,918,978/1,597,551, P=.027 and 0.002, respectively). However, no relationship between levels of the circulating cell-free DNA and the pathological parameters as well as CA 125 measurement in patients with epithelial ovarian cancer was found. A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA (mean of mitochondrial DNA 4,918,978/2,273,988 and mean of nuclear DNA 10,723/3,291, P=.013 and 0.105, respectively). CONCLUSION: Elevated levels of circulating cell-free nuclear DNA and circulating cell-free mitochondrial DNA in epithelial ovarian cancer may have diagnostic value. Our finding suggests that the circulating molecules might be potential biomarkers in the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, circulating mtDNA has been identified in patients with ovarian (Zachariah et al., 2008), testicular (Ellinger et al., 2009), prostate (Ellinger et al., 2009), and lung cancer (Hou et al., 2013).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Zachariah et al., 2008
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,174
Lo, Y. M. D., Tein, M. S. C., Lau, T. K., Haines, C. J., Leung, T. N., Poon, P. M. K., Wainscoat, J. S., Johnson, P. J., Chang, A. M. Z., & Hjelm, N. M. (1998) · The American Journal of Human Genetics · doi:10.1086/301800 · Cited by 1,653
Rapid Clearance of Fetal DNA from Maternal Plasma
Lo, Y. M. D., Zhang, J., Leung, T. N., Lau, T. K., Chang, A. M. Z., & Hjelm, N. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302205 · Cited by 1,157
Quantification of Free Circulating DNA As a Diagnostic Marker in Lung Cancer
Sozzi, G., Conte, D., Leon, M., Cirincione, R., Roz, L., Ratcliffe, C., Roz, E., Cirenei, N., Bellomi, M., Pelosi, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.006 · Cited by 552
Progress and Challenges in Screening for Early Detection of Ovarian Cancer
Jacobs, I. J., & Menon, U. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r400006-mcp200 · Cited by 458
Zhong, X. Y., Laivuori, H., Livingston, J. C., Ylikorkala, O., Sibai, B. M., Holzgreve, W., & Hahn, S. (2001) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2001.109594 · Cited by 284
Self-citationMalkasian, G. D., Knapp, R. C., Lavin, P. T., Zurawski, V. R., Podratz, K. C., Stanhope, C. R., Mortel, R., Berek, J. S., Bast, R. C., & Ritts, R. E. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(88)80081-4 · Cited by 227
Quantitative Analysis of Circulating Mitochondrial DNA in Plasma
Chiu, R. W. K., Chan, L. Y. S., Lam, N. Y. L., Tsui, N. B. Y., Ng, E. K. O., Rainer, T. H., & Lo, Y. M. D. (2003) · Clinical Chemistry · doi:10.1373/49.5.719 · Cited by 208
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
The Roles of Mitochondrial Damage-Associated Molecular Patterns in Diseases
Nakahira, K., Hisata, S., & Choi, A. M. K. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6407 · Cited by 360
“While the levels of circulating mtDNA are elevated in the patients with urological cancers (39, 98) and ovarian cancer (174), the levels of mtDNA are not increased in patients with Ewing sarcoma (173) or breast cancer (77).”
BackgroundCytoplasmic DNA: sources, sensing, and role in aging and disease
Miller, K. N., Victorelli, S. G., Salmonowicz, H., Dasgupta, N., Liu, T., Passos, J. F., & Adams, P. D. (2021) · Cell · doi:10.1016/j.cell.2021.09.034 · Cited by 288
Quantifying circulating cell-free DNA in humans
Meddeb, R., Dache, Z. A. A., Thezenas, S., Otandault, A., Tanos, R., Pastor, B., Sanchez, C., Azzi, J., Tousch, G., Azan, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41593-4 · Cited by 240
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients
Elshimali, Y., Khaddour, H., Sarkissyan, M., Wu, Y., & Vadgama, J. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918925 · Cited by 236
“A significant difference between the epithelial ovarian cancer and endometriosis group was found in circulating cell-free mitochondrial DNA but not in circulating cell-free nuclear DNA [46].”
BackgroundGrabuschnig, S., Bronkhorst, A. J., Holdenrieder, S., Rosales Rodriguez, I., Schliep, K. P., Schwendenwein, D., Ungerer, V., & Sensen, C. W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218062 · Cited by 222
“genomic and mitochondrial host DNA [3,4], as well as foreign DNA [5,6], for example, of bacterial or viral origin.”
BackgroundYu, M. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.010 · Cited by 216
“Similar changes in the level of serum ccf mtDNA have been noticed in patients diagnosed with epithelial ovarian cancer as compared to the corresponding cancer-free healthy group (Zachariah et al. 2008).”
ResultKohler, C., Radpour, R., Barekati, Z., Asadollahi, R., Bitzer, J., Wight, E., Bürki, N., Diesch, C., Holzgreve, W., & Zhong, X. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-105 · Cited by 215
“Changes in the level of ccf nDNA and mtDNA have been found in plasma and serum of patients with various cancer types [10,11].”
Self-citationHao, T. B., Shi, W., Shen, X. J., Qi, J., Wu, X. H., Wu, Y., Tang, Y. Y., & Ju, S. Q. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.470 · Cited by 187
“…compared with that in healthy individuals, which was also confirmed by other studies (Sozzi et al, 2003; Banki et al, 2007; Zhong et al, 2007; Zachariah et al, 2008; Ellinger et al, 2009; Hohaus et al, 2009; Paci et al, 2009; *Correspondence: Dr SQ Ju; E-mail: jsq814@hotmail.com Received 12…”
ResultDigital PCR analysis of circulating nucleic acids
Hudecova, I. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.03.015 · Cited by 178
“patients with epithelial ovarian cancers [104] and urological malignancies [103,105,106].”
BackgroundPlasma cell‐free DNA in ovarian cancer: An independent prognostic biomarker
Kamat, A. A., Baldwin, M., Urbauer, D., Dang, D., Han, L. Y., Godwin, A., Karlan, B. Y., Simpson, J. L., Gershenson, D. M., Coleman, R. L., et al. (2010) · Cancer · doi:10.1002/cncr.24997 · Cited by 169
“Zachariah and colleagues have reported elevated levels of both cell-free nuclear and mitochondrial DNA among ovarian cancer patients compared with controls, but levels of cell-free DNA did not correlate with prognosis in their cohort.(14) In the present study, we have shown that cell-free DNA 22,000 GE/mL is a powerfu…”
BackgroundAdvances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases
Boyapati, R. K., Tamborska, A., Dorward, D. A., & Ho, G.-T. (2017) · F1000Research · doi:10.12688/f1000research.10397.1 · Cited by 169
Mitochondrial DNA in extracellular vesicles declines with age
Lazo, S., Noren Hooten, N., Green, J., Eitan, E., Mode, N. A., Liu, Q., Zonderman, A. B., Ezike, N., Mattson, M. P., Ghosh, P., et al. (2021) · Aging Cell · doi:10.1111/acel.13283 · Cited by 163
“Thus far, most studies have examined ccf-mtDNA in serum or plasma (Boyapati et al., 2017) and used only one primer set (Lee et al., 2010; Pinti et al., 2014; Zachariah et al., 2008).”
BackgroundForms of extracellular mitochondria and their impact in health
Miliotis, S., Nicolalde, B., Ortega, M., Yepez, J., & Caicedo, A. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.02.002 · Cited by 138
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients
Marzese, D. M., Hirose, H., & Hoon, D. S. �. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.845088 · Cited by 131
“…et al. (2012) [123] Melanoma Pinzani et al. (2011) Salvianti et al. (2012) Perkins et al. (2012) Perkins et al. (2012) [61,115] [111] [115] Ovarian Zachariah et al. (2008) Perkins et al. (2012) Kamat et al. (2010) Perkins et al. (2012) [124,125] [115] Lung Paci et al. (2009) Ulivi et al. (2013)…”
Circulating Nucleic Acids in Plasma and Serum: Recent Developments
Gahan, P. B., & Swaminathan, R. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1448.050 · Cited by 121
Screening for ovarian cancer: imaging challenges and opportunities for improvement
Mathieu, K. B., Bedi, D. G., Thrower, S. L., Qayyum, A., & Bast, R. C. (2017) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.17557 · Cited by 134
Ellinger, J., Müller, D. C., Müller, S. C., Hauser, S., Heukamp, L. C., von Ruecker, A., Bastian, P. J., & Walgenbach‐Brünagel, G. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.03.004 · Cited by 122
RYKOVA, E. Y., Morozkin, E. S., Ponomaryova, A. A., Loseva, E. M., Zaporozhchenko, I. A., Чердынцева, Н. В., Vlassov, V. V., & Laktionov, P. P. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.673577 · Cited by 110
Elevated Levels of Cell-Free Circulating DNA in Patients with Acute Dengue Virus Infection
Ha, T. T. N., Huy, N. T., Murao, L. A. E., Lan, N. T. P., Thúy, T. T., Tuấn, H. M., Nga, C. T. P., Tuong, V. V., Dat, T. V., Kikuchi, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025969 · Cited by 97
“protocol previously published in which the copy number of the GAPDH gene was used to represent the DNA level in the plasma [16,32] (at least 400 ml of plasma was used; details of the method are described in the Methods S1).”
BackgroundMethodInfluentialCirculating cell-free DNA content as blood based biomarker in endometrial cancer
Cicchillitti, L., Corrado, G., Angeli, M. D., Mancini, E., Baiocco, E., Patrizi, L., Zampa, A., Merola, R., Martayan, A., Conti, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23247 · Cited by 110
Li, L., Hann, H.-W., Wan, S., Hann, R. S., Wang, C., Lai, Y., Ye, X., Evans, A., Myers, R. E., Ye, Z., et al. (2016) · Scientific Reports · doi:10.1038/srep23992 · Cited by 94
Circulating cell-free mitochondrial DNA levels in Parkinson’s disease are influenced by treatment
Lowes, H., Pyle, A., Santibanez-Koref, M., & Hudson, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00362-y · Cited by 91
“Based on prior association [19], where mean log [10] ccf-mtDNA per microliter was 1.”
BackgroundMethodInfluentialCirculating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges
Yu, M. (2012) · Mitochondrial DNA · doi:10.3109/19401736.2012.696625 · Cited by 94
“Considering that ccf nDNA levels were elevated in patients with epithelial ovarian cancer (Zachariah et al. 2008), testicular cancer (Ellinger et al.”
BackgroundHigh-throughput approaches for precision medicine in high-grade serous ovarian cancer
Govindarajan, M., Wohlmuth, C., Waas, M., Bernardini, M. Q., & Kislinger, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00971-6 · Cited by 96
Giannopoulou, L., Kasimir-Bauer, S., & Lianidou, E. S. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0019 · Cited by 84
“Interestingly, they reported a significant difference between ovarian cancer patients and the endometriosis group circulating cell-free mtDNA, but not in nuclear cfDNA [48].”
BackgroundZhou, Q., Li, W., Leng, B., Zheng, W., He, Z., Zuo, M., & Chen, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155495 · Cited by 90
Keserű, J. S., Soltész, B., Lukács, J., Márton, É., Szilágyi, M., Penyige, A., Póka, R., & Nagy, B. (2019) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2019.04.015 · Cited by 84
The evolution and ecology of benign tumors
Boutry, J., Tissot, S., Újvári, B., Capp, J., Giraudeau, M., Nedelcu, A. M., & Thomas, F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188643 · Cited by 111
Nucleic acids in circulation: Are they harmful to the host?
Mittra, I., Nair, N. K., & Mishra, P. K. (2012) · Journal of Biosciences · doi:10.1007/s12038-012-9192-8 · Cited by 83
Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology
García-Olmo, D. C., González-Masiá, & García‐Olmo, D. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s44668 · Cited by 85
“Moreover, several studies have suggested that quantitation of mitochondrial cfDNA in plasma might serve as a clinical tool,(117,118) and may even have a higher diagnostic value than gDNA in some cases.(118) Specifically, Kohler et al(117) compared the levels of gDNA and mitDNA in plasma from patients with benign and m…”
BackgroundUse of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer
Ganepola, G. A. P., Nizin, J. S., Rutledge, J. R., & Chang, D. (2014) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v6.i4.83 · Cited by 78
Somatic Mitochondrial DNA Mutations in Human Cancers
Yu, M. (2012) · Advances in clinical chemistry · doi:10.1016/b978-0-12-394384-2.00004-8 · Cited by 80
Mitochondrial Dysfunction in Cancer Cells Due to Aberrant Mitochondrial Replication
Shapovalov, Y., Hoffman, D. L., Zuch, D. T., Bentley, K. L. D. M., & Eliseev, R. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.250092 · Cited by 79
Micrometastasis in gastric cancer
Zhang, Z.-Y., & Ge, H. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.021 · Cited by 72
“Thus, altered expression of CTCs markers may be helpful to diagnose cancer [118,119].”
BackgroundTraver, S., Assou, S., Scalici, E., Haouzi, D., Al-Edani, T., Belloc, S., & Hamamah, S. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu031 · Cited by 73
“Interestingly, patients with EOC or endometriosis have significantly different levels of circulating cell-free mitochondrial DNA, but not of circulating cell-free nuclear DNA (Zachariah et al., 2008). cfDNA originating from promotors can be methylated.”
BackgroundChen, Q., Zhang, Z., Wang, S., & Lang, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s227156 · Cited by 83
“Quantitative alterations of circulating cell-free nuclear DNA and circulating cellfree mitochondrial DNA were evaluated to confirm their values in diagnosing OC with moderate sensitivity and specificity.(37) Dobrzycka et al found that the detection rate of ovarian serous carcinoma was higher than other types, suggesti…”
BackgroundSteffensen, K. D., Madsen, C. V., Andersen, R. F., Waldstrøm, M., Adimi, P., & Jakobsen, A. K. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.022 · Cited by 59
“There are a few studies [18–21] that illustrate the diagnostic value of cfDNA investigating the hypothesis that cfDNA is higher in the blood of patients with ovarian cancer than in patients with benign ovarian tumours and healthy controls.”
ResultPrediction of Clear Cell Renal Cell Carcinoma by Integrity of Cell-free DNA in Serum
Gang, F., Guorong, L., Zhao, A., Gentil‐Perret, A., Christian, G., & Jacques, T. (2009) · Urology · doi:10.1016/j.urology.2009.06.048 · Cited by 60
Polívka, J., Pešta, M., & Jankú, F. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1110021 · Cited by 58
“[22,23] It has been demonstrated that patients with advanced cancer have higher levels of cfDNA than patients with localized cancer or individuals without cancer.[24-34] DNA can enter the circulation by several distinct mechanisms, including release of nuclear and mitochondrial DNA from dying cells during either apopt…”
BackgroundCell-free DNA level as a prognostic biomarker for epithelial ovarian cancer.
No, J. H., Kim, K., Park, K. H., & Kim, Y. B. (2012) · PubMed · Cited by 63
Yu, M., Wan, Y., & Zou, Q. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.06.007 · Cited by 51
“ovarian cancer patients had significantly elevated amounts of plasma ccf mtDNA compared with those with benign ovarian diseases and healthy controls (16).”
BackgroundCirculating Mitochondrial DNA is Linked to Progression and Prognosis of Epithelial Ovarian Cancer
Meng, X., Schwarzenbach, H., Yang, Y., Müller, V., Li, N., Tian, D., Shen, Y., & Gong, Z. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.05.015 · Cited by 48
“demonstrated that the quantities of plasma mtDNA in EOC were elevated compared with a healthy control group, and had the capacity to discriminate between EOC patients and healthy individuals with a sensitivity of 63% and a specificity of 62% [18].”
BackgroundTracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures
Oberhofer, A., Bronkhorst, A. J., Uhlig, C., Ungerer, V., & Holdenrieder, S. (2022) · Diagnostics · doi:10.3390/diagnostics12081834 · Cited by 52
Mahmoud, E. H., Fawzy, A., Ahmad, O. K., & Ali, A. M. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.18.8299 · Cited by 48
“CA 15-3 is elevated in 69% of advanced breast cancer cases; its role in cancer screening is limited, being elevated in other malignancies including pancreatic (Hampton, 2007), ovarian (Zachariah et al., 2008), lung”
BackgroundCirculating cell-free DNA in serum as a biomarker of colorectal cancer
Filho, B. F. D. S., Gurgel, A. P. A. D., Neto, M. Á. D. F. L., de Azevedo, D. A., de Freitas, A. C., Neto, J. D. C. S., & da Silva, L. A. F. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2013-201521 · Cited by 46
Prognostic biomarkers in ovarian cancer
Huang, J., Hu, W., & Sood, A. K. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0212 · Cited by 53
“and mitochondrial DNA in ovarian cancer patients than in healthy controls but no correlation between cell-free DNA and prognosis [257].”
BackgroundBiological markers of prognosis, response to therapy and outcome in ovarian carcinoma
Szajnik, M. E., Czystowska, M., Elishaev, E., & Whiteside, T. L. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1194758 · Cited by 42
Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA
Weerts, M. J. A., Timmermans, E. C., van de Stolpe, A., Vossen, R. H. A. M., Anvar, S. Y., Foekens, J. A., Sleijfer, S., & Martens, J. W. M. (2018) · Neoplasia · doi:10.1016/j.neo.2018.05.003 · Cited by 42
Li, B., Pu, K., Ge, L., & Wu, X. (2019) · Gene · doi:10.1016/j.gene.2019.143993 · Cited by 41
Role of Circulating Free Alu DNA in Endometrial Cancer
Tanaka, H., Tsuda, H., Nishimura, S., Nomura, H., Kataoka, F., Chiyoda, T., Tanaka, K., Iguchi, Y., Susumu, N., & Aoki, D. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182328c94 · Cited by 40
Evaluation of Digital PCR as a Technique for Monitoring Acute Rejection in Kidney Transplantation
Lee, H., Park, Y.-M., Wee, Y., Han, D. J., Seo, J.-W., Moon, H., Lee, Y.-H., Kim, Y., Moon, J.-Y., Lee, S. H., et al. (2017) · Genomics & Informatics · doi:10.5808/gi.2017.15.1.2 · Cited by 39
“It has been reported that mtDNA concentration is highly affected by the blood-processing protocol [23], and no correlation was also observed between the levels of circulating mtDNA and genomic DNA in previous studies [24, 25].”
BackgroundDiagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
Červená, K., Vodička, P., & Vymetalkova, V. P. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2019.05.002 · Cited by 44
Παναγοπούλου, Μ., Esteller, M., & Chatzaki, Ε. (2021) · Cancers · doi:10.3390/cancers13040728 · Cited by 39
Ma, X., Zhu, L., Wu, X., Bao, H., Wang, X., Chang, Z., Shao, Y. W., & Wang, Z. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169231 · Cited by 40
Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers
Dobrzycka, B., Terlikowski, S. J., Kinalski, M., Kowalczuk, O., Niklińska, W., & Chyczewski, L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq584 · Cited by 39
Cell-Free DNA—A Marker to Predict Ischemic Brain Damage in a Rat Stroke Experimental Model
Boyko, M., Ohayon, S., Goldsmith, T., Douvdevani, A., Gruenbaum, B. F., Melamed, I., Knyazer, B., Shapira, Y., Teichberg, V. I., Elir, A., et al. (2011) · Journal of Neurosurgical Anesthesiology · doi:10.1097/ana.0b013e31821b536a · Cited by 33
Clinical application of plasma mitochondrial DNA content in patients with lung cancer
Chen, J., Zhang, L., Yu, X., Zhou, H., Luo, Y., Wang, W., & Wang, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9515 · Cited by 37
“In related work, no relationship between mtDNA content and serum prostate‑specific antigen levels has been identified in prostate cancer and epithelial ovarian cancer (18,47).”
The mitochondrial landscape of ovarian cancer: emerging insights
Shukla, P., & Singh, K. K. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab033 · Cited by 32
Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients
Kaľavská, K., Minařík, T., Vlková, B., Manasova, D., Kubičková, M., Jurik, A., Mardiak, J., Šufliarský, J., Celec, P., & Mego, M. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0459-z · Cited by 31
Assessment of EGFR mutation status using cell-free DNA from bronchoalveolar lavage fluid
Park, S., Hur, J. Y., Lee, K. Y., Lee, J. C., Rho, J. K., Shin, S. H., & Choi, C. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0302 · Cited by 33
The Uprising of Mitochondrial DNA Biomarker in Cancer
Khair, S. Z. N. M., Radzak, S. M. A., & Yusoff, A. A. M. (2021) · Disease Markers · doi:10.1155/2021/7675269 · Cited by 36
“Analyzed cf-mtDNA as diagnostic and prognostic bio-marker in epithelial ovarian cancer showed signi fi cantly higher levels in cancer patients than healthy controls [158, 159].”
Advances in Circulating Tumor DNA Analysis
Perakis, S. O., Auer, M., Belic, J., & Heitzer, E. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2016.11.005 · Cited by 39
Lou, X., Hou, Y., Liang, D., PENG, L., Chen, H., MA, S., & Zhang, L. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1991 · Cited by 31
“It has been reported that the levels of cfDNA in serum and plasma are significantly increased in patients with colorectal, ovarian and testicular cancer (6-8).”
BackgroundPotential clinical applications of circulating cell-free DNA in ovarian cancer patients
Barbosa, A. P. F., Peixoto, A., Pinto, P., Pinheiro, M., & Teixeira, M. R. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.5 · Cited by 29
Pasha, H. A., Rezk, N. A., & Riad, M. A. (2019) · Cancer Investigation · doi:10.1080/07357907.2019.1663864 · Cited by 25
“Recently, changes in the level of circulating cell free nuclear DNA (nDNA), mitochondrial DNA (mtDNA) [9,10] and global DNA methylation status [11–13] have received considerable attention as a resource of cancer biomarkers in plasma and serum of patients with various cancers [14].”
BackgroundCurrent Trends in Cell-Free DNA Applications. Scoping Review of Clinical Trials
Stawski, R. S., Stec‐Martyna, E., Chmielecki, A., Nowak, D., & Perdas, E. (2021) · Biology · doi:10.3390/biology10090906 · Cited by 28
Park, S. S., Jeong, H., & Andreazza, A. C. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1938214 · Cited by 32
“…such as improved precision (Yu 2012). ccf-mtDNA was first deliberately investigated in diseases like cancer (Takeuchi et al. 2004; Mehra et al. 2007; Zachariah et al. 2008), inflammatory diseases (Pyle et al. 2010; Zhang et al. 2010), cardiovascular diseases (Tsai et al. 2011; Arnalich et al.…”
BackgroundPerdas, E., Stawski, R. S., Kaczka, K., Nowak, D., & Zubrzycka, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-51000-7 · Cited by 24
Cheng, Y.-H., Wang, C., Hsu, K., & Lee, G. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c04988 · Cited by 24
Kirimli, C. E., Shih, W., & Shih, W. Y. (2014) · The Analyst · doi:10.1039/c4an00215f · Cited by 22
Post-mortem ventricular cerebrospinal fluid cell-free-mtDNA in neurodegenerative disease
Lowes, H., Kurzawa-Akanbi, M., Pyle, A., & Hudson, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-72190-5 · Cited by 21
Generation, function, and prognostic utility of somatic mitochondrial DNA mutations in cancer
Kulawiec, M., Salk, J. J., Ericson, N. G., Wanagat, J., & Bielas, J. H. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20582 · Cited by 21
“Similar changes in the level of circulating cfmtDNA have been found in plasma and serum of patients with a variety of different cancer types [Wu et al., 2002; Zachariah et al., 2008].”
BackgroundChoudhuri, S., Sharma, C., Banerjee, A., Kumar, S., Kumar, L., & Singh, N. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1863-8 · Cited by 20
“A consistent correlation between tumor burden and quantity of CFDNA has been observed in EOC [2, 15, 16].”
BackgroundLehle, S., Emons, J., Hack, C. C., Heindl, F., Hein, A., Preuß, C., Seitz, K., Zahn, A. L., Beckmann, M. W., Fasching, P. A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-022-27216-5 · Cited by 21
Radpour, R., & Forouharkhou, F. (2018) · World Journal of Stem Cells · doi:10.4252/wjsc.v10.i11.160 · Cited by 20
Self-citationCell-Free DNA: Potential Application in COVID-19 Diagnostics and Management
Stawski, R. S., Nowak, D., & Perdas, E. (2022) · Viruses · doi:10.3390/v14020321 · Cited by 18
“Moreover, cfDNA helps to distinguish between malignant and benign neoplasia, as well as controls, tumor type, grade, lymph node status, primary tumor, and metastases of many organs, glands, and tissues, including breast [63–65], prostate [66], colon [67], liver [68], ovary [69,70], endometrium [71], thyroid [72], and…”
BackgroundMorales, J. J., Korucu, B., Pike, M., Lipworth, L. P., Stewart, T. G., Headley, S., Germain, M., Begue, G., Roshanravan, B., Tuttle, K. R., et al. (2021) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00270.2021 · Cited by 19
Liquid biopsy in ovarian cancer
Giannopoulou, L., & Lianidou, E. S. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.01.001 · Cited by 16
Amniotic fluid cell‐free DNA in preterm prelabor rupture of membranes
Kacerovský, M., Vlková, B., Musilova, I. K., Andrýs, C., Plíšková, L., Žemličková, H., Stráník, J., Halada, P., Jacobsson, B., & Celec, P. (2018) · Prenatal Diagnosis · doi:10.1002/pd.5366 · Cited by 15
Clinical significance of serum mitochondrial DNA in lung cancer
Hou, Y.-L., Chen, J.-J., Wu, Y.-F., Xue, C.-J., Li, F.-Z., Zheng, Q., & Chen, H. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.04.009 · Cited by 13
Daubermann, C., Herhaus, B., Neuberger, E. W. I., Simon, P. D., & Petrowski, K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10369-7 · Cited by 17
“Serval studies highlight its prognostic and diagnostic potential in pathological conditions including cancer [33], neurodegenerative diseases [34], mood disorders [35], and infectious conditions.”
Prognostic value of circulating mitochondrial DNA in prostate cancer and underlying mechanism
Borah, S., Mishra, R., Dey, S., Suchanti, S., Bhowmick, N. A., Giri, B., & Haldar, S. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.05.005 · Cited by 13
Mitochondrial Fraction of Circulating Cell-Free DNA as an Indicator of Human Pathology
Παναγοπούλου, Μ., Karaglani, M., Tzitzikou, K., Kessari, N., Arvanitidis, K. I., Amarantidis, K., Drosos, G. I., Gerou, S., Παπάνας, Ν., Papazoglou, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084199 · Cited by 14
“For example, levels of ccf - mtDNA were quantified to be elevated in different cancer types [8–11], including Breast Cancer (BrCa) [12, Aberrant ccf-mtDNA levels have also been reported in other diseases, such as Alzheimer’s [15].”
BackgroundCabral, R. E. C. (2010) · The Open Lung Cancer Journal · doi:10.2174/1876819901003010038 · Cited by 12
Generation of blood circulating DNAs: Sources, features of struction and circulation
Bryzgunova, O. E., & Laktionov, P. P. (2014) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750814030020 · Cited by 12
The Role of Circulating Tumor DNA in Ovarian Cancer
Golara, A., Kozłowski, M., & Cymbaluk‐Płoska, A. (2024) · Cancers · doi:10.3390/cancers16183117 · Cited by 13
“Nevertheless, in patients with epithelial ovarian cancer, there was no correlation observed between the measurement of CA 125 and pathological characteristics or the amount of circulating cell-free DNA [65].”
BackgroundProfiling disease and tissue-specific epigenetic signatures in cell-free DNA
Oberhofer, A., Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2022) · Journal of Laboratory Medicine · doi:10.1515/labmed-2022-0031 · Cited by 9
Mitochondrial DNA Mutations and Ageing
Whitehall, J. C., Smith, A. L. M., & Greaves, L. C. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-21410-3_4 · Cited by 10
Generation of blood circulating DNA: the sources, peculiarities of circulation and structure
Bryzgunova, O. E., & Laktionov, P. P. (2015) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20156104409 · Cited by 9
Neutrophil extracellular traps in diseases of the female reproductive organs
Morawiec, M.-L., Kubina, R., Stępień, S., Smycz‐Kubańska, M., Królewska‐Daszczyńska, P., Ratajczak–Wrona, W., & Mielczarek‐Palacz, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589329 · Cited by 11
Feng, Y., Yang, W., Zhu, J., Wang, S., Wu, N., Zhao, H., & Yang, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1594100 · Cited by 9
Czegle, I., Huang, C., Soria, P., Purkiss, D., Shields, A., & Wappler-Guzzetta, E. A. (2023) · Life · doi:10.3390/life13040996 · Cited by 13
Carcinoma of the Ovaries and Fallopian Tubes
Coleman, R. L., Liu, J., Matsuo, K., Thaker, P. H., Westin, S. N., & Sood, A. K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00086-4 · Cited by 9
Guo, Q., & Hua, Y. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0193 · Cited by 8
Khadka, P., Young, C. K. J., Sachidanandam, R., Brard, L., & Young, M. J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394699 · Cited by 8
Huebner, H., Lubrich, H., Blum, S., Antoniadis, S., Lermann, J., Ekici, A. B., Fasching, P. A., Beckmann, M. W., Ruebner, M., & Burghaus, S. (2021) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2021.08.004 · Cited by 7
Şahin, F., Breinbauer, R., Linnemann, C., Tombaz, M., Nussler, A. K., & Ehnert, S. (2025) · Methods and Protocols · doi:10.3390/mps8020042 · Cited by 8
“It is well established that mitochondrial DNA can also be released during NET release, albeit in much smaller quantities compared with genomic DNA [40].”
Liu, Y., Ma, X., Guan, Q., & Zhou, S. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1774015 · Cited by 7
Pehlıvan, S. (2012) · Biochemistry & Physiology Open Access · doi:10.4172/2168-9652.1000e109 · Cited by 5
Metadata
- Authors
- Zachariah, R. R., Schmid, S., Buerki, N., Radpour, R., Holzgreve, W., & Zhong, X.
- Affiliations
- University of Basel (CH)
- Venue
- Obstetrics & Gynecology
- Published
- 2008-10
- Volume
- 112
- Issue
- 4
- Pages
- 843-850
- ISSN
- 0029-7844 (ISSN-L)
- OpenAlex
- W2076316408
- Cited by
- 142
- References
- 25
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 5 · 2021: 18 · 2020: 8 · 2019: 12 · 2018: 8 · 2017: 10 · 2016: 6 · 2015: 6 · 2014: 7 · 2013: 8 · 2012: 11
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Obstetrics and Gynecology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- cell-free DNA, cell-free mitochondrial DNA, epithelial ovarian cancer, benign ovarian tumors, endometriosis, liquid biopsy, tumor markers, CA125
- MeSH terms
- Adult, Cell-Free System, DNA, Mitochondrial, DNA, Neoplasm, Endometriosis, Female, Humans, Ovarian Neoplasms, ROC Curve, Biomarkers, Tumor, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.